Refixia
nonacog beta pegol · Novo Nordisk A/S
AUTHORISED IN THE EUWhat Refixia is used for
Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency). Refixia can be used for all age groups.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Refixia
- Active substance
- nonacog beta pegol
- Disease area
- Hemophilia B
- Medicine group
- Antihemorrhagics
- ATC code
- B02BD04
- Marketing authorisation holder
- Novo Nordisk A/S
- Authorised in the EU since
- 2017
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Refixia used for?
Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency). Refixia can be used for all age groups.
What is the active substance in Refixia?
Refixia contains nonacog beta pegol.
Who makes Refixia?
The EU marketing authorisation holder is Novo Nordisk A/S.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU